medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-6-84-86medsovet-1890Research ArticleХимиотерапия злокачественных опухолейMalignant tumor chemotherapyТЕЙСУНО В ПЕРВОЙ ЛИНИИ ТЕРАПИИ ДИССЕМИНИРОВАННОГО РАКА ЖЕЛУДКАTEYSUNO: FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH DISSEMINATED GASTRIC CANCERГОРДЕЕВАО. О.GORDEEVAO. O.АБРАМОВМ. Е.ABRAMOVM. E.

к.м.н.

PhD in medicine

ЛУДА. Н.LUDA. N.

к.м.н.

PhD in medicine

Российский онкологический научный центр им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaRussian Federation201719062017068486Copyright © ГОРДЕЕВА О.О., АБРАМОВ М.Е., ЛУД А.Н., 20172017ГОРДЕЕВА О.О., АБРАМОВ М.Е., ЛУД А.Н.GORDEEVA O.O., ABRAMOV M.E., LUD A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1890

Рак желудка – одна из лидирующих причин смерти среди злокачественных образований в России. Имеющиеся на данный момент терапевтические подходы не приводят к значимому увеличению безрецидивной и общей выживаемости. На данный момент существует необходимость в поиске новых препаратов для лечения пациентов с этим заболеванием. Препарат Тейсуно (тегафур/гимерацил/отерацил, ТГО) продемонстрировал свою эффективность в первой линии лечения пациентов с диссеминированным раком желудка и некоторых других злокачественных новообразований. Препарат был зарегистрирован в Японии, США, Европе, а также в Российской Федерации. Внедрение в клиническую практику большего количества химиотерапевтических агентов расширяет терапевтические возможности для этой группы пациентов.

Gastric cancer is one of the leading causes of death among all cancers in Russia. Progression-free and overall survival cannot be drastically changed by current therapeutic approaches. There is a strong need in new drugs for that disease. Teysuno has demonstrated its efficacy in treatment of advanced gastric cancer and some other cancers. The more drugs we obtain for clinical practice the more opportunities we can offer for these patients.

рак желудкаТейсунофторпиримидиныgastric cancerTeysunofluoropyrimidinesReferencesЗлокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017.Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017.The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. European Journal of Cancer, 2013, 49: 1565–1577.The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. European Journal of Cancer, 2013, 49: 1565–1577.Cunningham D, Starling N, Rao S et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med, 2008, 358: 36-46.Cunningham D, Starling N, Rao S et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med, 2008, 358: 36-46.Chap LI, Laux I, VanVugt A, et al: A phase I study of S-1 GI toxicity with and without oxonic acid (Oxo). J Clin Oncol, 2008, 26: 623s (abstr 13539).Chap LI, Laux I, VanVugt A, et al: A phase I study of S-1 GI toxicity with and without oxonic acid (Oxo). J Clin Oncol, 2008, 26: 623s (abstr 13539).Saif MW, Rosen LS, Zhang J, et al: A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics (PK) of 5-fluorouracil (5-FU). J Clin Oncol, 2008, 26: 115s, (abstr 2514).Saif MW, Rosen LS, Zhang J, et al: A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics (PK) of 5-fluorouracil (5-FU). J Clin Oncol, 2008, 26: 115s, (abstr 2514).Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol, 2010, 28: 1547-53.Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol, 2010, 28: 1547-53.Ajani JA, Buyse M, Lichinitser M et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluoroura cil in the First-Line Advanced Gastric Cancer Study. European Journal of Cancer, 2013, 4: 3616-3624.Ajani JA, Buyse M, Lichinitser M et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluoroura cil in the First-Line Advanced Gastric Cancer Study. European Journal of Cancer, 2013, 4: 3616-3624.György Bodoky, Max E. Scheulen, Fernando Rivera et al. Clinical Benefit and Health- Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer, 2015 Jun, 46(2): 109-17.György Bodoky, Max E. Scheulen, Fernando Rivera et al. Clinical Benefit and Health- Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer, 2015 Jun, 46(2): 109-17.Ryu M-H, Baba E, Lee KH. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Annals of Oncology, 2015, 26: 2097-2101.Ryu M-H, Baba E, Lee KH. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Annals of Oncology, 2015, 26: 2097-2101.Matsusaka S, Kobunai T, Yamamoto N et al. Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. Genes & Cancer, 2016 January, 7(1-2).Matsusaka S, Kobunai T, Yamamoto N et al. Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. Genes & Cancer, 2016 January, 7(1-2).Shen X-M, Zhou C, Lian L et al. Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer. Cell Biochemistry and Biophysics, 2015, 71(3): 1653–1661.Shen X-M, Zhou C, Lian L et al. Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer. Cell Biochemistry and Biophysics, 2015, 71(3): 1653–1661.Yamada Y, Higuchi K, Nishikawa K et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Annals of Oncology, 2014, 00: 1-8.Yamada Y, Higuchi K, Nishikawa K et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Annals of Oncology, 2014, 00: 1-8.Бяхов М. Ю., Бесова Н. С., Владимирова Л. Ю., Волков Н. М., Левченко Е. В., Сакаева Д. Д. и соавт. Практические рекомендации по лекарственному лечению рака желудка. Злокачест вен ные опухоли, 2016, 4 (Спецвыпуск 2): 234-247.Бяхов М. Ю., Бесова Н. С., Владимирова Л. Ю., Волков Н. М., Левченко Е. В., Сакаева Д. Д. и соавт. Практические рекомендации по лекарственному лечению рака желудка. Злокачест вен ные опухоли, 2016, 4 (Спецвыпуск 2): 234-247.Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D. Gastric Cancer: ESMO Clinical Practice Guidelines. Ann Oncol, 2016, 27(suppl 5): v38-v49.Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D. Gastric Cancer: ESMO Clinical Practice Guidelines. Ann Oncol, 2016, 27(suppl 5): v38-v49.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer Version 3.2016.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer Version 3.2016.

The authors declare that there are no conflicts of interest present.